There are two alternatives under atypical squamous cells on the TCT report form, one is not clearly meaningful and the other is inclined to be highly pathological. That is, ASC includes both ASCUS and ASC-H categories. Cervical atypical squamous cells do not exclude (tend to) high intraepithelial lesions, i.e. ASC-H. According to evidence from evidence-based medicine, 30-90% of patients with ASC-H have ClN2/3. Therefore, direct colposcopic multi-point biopsy for evidence of pathology is usually performed in this group of patients and is considered the gold standard. If colposcopic biopsy is negative, repeat cytology at month 6 and month 12 or high-risk HPV at month 12 is recommended, followed by colposcopy in case of abnormalities, and if not, routine follow-up.